Mounjaro vs Wegovy: Clinical Evidence | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro vs Wegovy UK Price £124.99

Compare clinical evidence and get the cheapest UK price on Mounjaro from £124.99 plus £20 off with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Mounjaro vs Wegovy: Clinical Evidence Comparison

Published on: June 03, 2026

When evaluating mounjaro vs wegovy clinical evidence uk, understanding the head-to-head trial data is essential for making an informed treatment decision. Both medications are licensed by the MHRA for weight management, but their mechanisms, clinical outcomes, and side effect profiles differ significantly. Our UK pharmacists have analysed the published research to help you understand which option may suit your needs, subject to prescriber approval.

Understanding the Mounjaro vs Wegovy Clinical Evidence

Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to the GLP-1 receptor agonist class, but tirzepatide uniquely activates both GIP and GLP-1 receptors, creating a dual-pathway mechanism [1]. This fundamental difference in pharmacology translates to measurably different clinical outcomes in published trials.

The landmark SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in adults with type 2 diabetes, demonstrating superior weight reduction with the highest tirzepatide dose [1]. Patients receiving tirzepatide 15mg achieved an average 12.4kg weight loss over 40 weeks, compared to 6.2kg with semaglutide 1mg — a statistically significant difference that has informed UK prescribing decisions.

For obesity-specific indications, the SURMOUNT-1 trial evaluated tirzepatide in adults without diabetes, showing average weight reductions of 15.0%, 19.5%, and 22.5% with 5mg, 10mg, and 15mg doses respectively over 72 weeks [2]. These results exceeded those seen in the STEP trials for semaglutide, which reported average reductions of 14.9% at the 2.4mg dose over 68 weeks [3].

Head-to-Head Trial Results: SURPASS-2 Analysis

The SURPASS-2 study remains the only published direct comparison of tirzepatide versus semaglutide, providing the strongest mounjaro vs wegovy clinical evidence available to UK prescribers [1]. This randomised controlled trial enrolled 1,879 adults with type 2 diabetes and elevated BMI, comparing three tirzepatide doses (5mg, 10mg, 15mg) against semaglutide 1mg over 40 weeks.

Primary endpoints included HbA1c reduction and body weight change. All three tirzepatide doses demonstrated superior efficacy for both outcomes, with the 15mg dose producing mean weight loss of 5.5kg more than semaglutide [1]. Importantly, 31.7% of participants on tirzepatide 15mg achieved at least 15% body weight reduction, compared to just 16.2% on semaglutide.

Safety profiles were comparable between treatments, with gastrointestinal side effects being the most commonly reported in both groups [1]. Nausea occurred in 17-22% of tirzepatide participants versus 18% with semaglutide, suggesting similar tolerability despite the enhanced efficacy observed with the dual agonist mechanism.

Statistical Significance and Clinical Relevance

The weight loss differences observed in SURPASS-2 were not only statistically significant (p<0.001) but also clinically meaningful [1]. A 5-10% body weight reduction is associated with improvements in cardiovascular risk factors, whilst reductions exceeding 15% can produce remission of obesity-related comorbidities such as sleep apnoea and fatty liver disease. The higher proportion of participants achieving this threshold with tirzepatide represents a tangible clinical advantage when selecting between treatments.

SURMOUNT vs STEP Trials: Obesity-Specific Evidence

For patients without diabetes seeking weight management, the SURMOUNT and STEP trial programmes provide the most relevant mounjaro vs wegovy clinical evidence. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related comorbidity, excluding those with diabetes [2]. Participants received tirzepatide 5mg, 10mg, 15mg, or placebo alongside lifestyle intervention.

At 72 weeks, the tirzepatide 15mg group achieved mean weight reduction of 22.5% from baseline — the highest reported in any obesity pharmacotherapy trial to date [2]. By comparison, the STEP 1 trial of semaglutide 2.4mg reported mean reduction of 14.9% at 68 weeks [3]. Both trials used similar inclusion criteria and lifestyle intervention protocols, making this comparison particularly informative for UK prescribers.

Secondary endpoints further distinguished the treatments. In SURMOUNT-1, 55% of participants on tirzepatide 15mg achieved at least 20% weight loss, versus 35% in STEP 1 with semaglutide 2.4mg [2][3]. These proportions matter clinically, as greater weight loss correlates with more substantial improvements in cardiometabolic health markers including blood pressure, lipid profiles, and inflammatory biomarkers.

Factor Mounjaro (Tirzepatide) Wegovy (Semaglutide)
Mechanism Dual GIP/GLP-1 receptor agonist GLP-1 receptor agonist
Average weight loss (obesity trials) 22.5% at 15mg dose (72 weeks) 14.9% at 2.4mg dose (68 weeks)
Head-to-head trial Superior to semaglutide 1mg (SURPASS-2) Comparator in SURPASS-2
Injection frequency Once weekly Once weekly
Common side effects Nausea, diarrhoea, vomiting (60-80%) Nausea, diarrhoea, vomiting (60-80%)
Starting price at Cured Pharmacy From £69.00 From £69.00
MHRA licensed indication Weight management + type 2 diabetes Weight management

Side Effect Profiles: What the Clinical Evidence Shows

Gastrointestinal adverse events dominate the safety profiles of both medications, occurring in 60-80% of trial participants across studies [1][2][3]. Nausea, diarrhoea, vomiting, and constipation are the most frequently reported, typically emerging during dose escalation and diminishing over subsequent weeks.

In SURPASS-2, discontinuation rates due to adverse events were 4.3-6.2% across tirzepatide doses compared to 3.2% with semaglutide 1mg [1]. SURMOUNT-1 reported discontinuation rates of 4.3-6.2% with tirzepatide versus 2.6% with placebo [2], whilst STEP 1 showed 4.5% discontinuation with semaglutide 2.4mg [3]. These similar rates suggest comparable real-world tolerability despite tirzepatide's dual mechanism.

Serious adverse events occurred in fewer than 7% of participants across all trials, with no consistent pattern distinguishing tirzepatide from semaglutide [1][2][3]. Pancreatitis, gallbladder disorders, and hypoglycaemia (when combined with insulin or sulphonylureas) remain theoretical concerns with all GLP-1 receptor agonists, though incidence in clinical trials has been low. UK prescribers assess individual risk factors before initiating either treatment.

Managing Common Side Effects

Both medications employ gradual dose escalation protocols specifically designed to minimise gastrointestinal symptoms. Mounjaro typically starts at 2.5mg weekly for four weeks before increasing, whilst Wegovy begins at 0.25mg with monthly increments [4]. Patients who experience persistent nausea or vomiting should contact their prescriber, as dose adjustment or temporary hold may be appropriate. Adequate hydration and eating smaller, more frequent meals can help manage these effects during the initial weeks.

Long-Term Efficacy and Weight Maintenance Evidence

Sustaining weight loss beyond the initial trial period remains a critical consideration when evaluating mounjaro vs wegovy clinical evidence. Extension studies and real-world data provide insight into durability of effect with continued treatment.

The SURMOUNT-1 trial demonstrated continued weight reduction through 72 weeks, with no plateau observed in the final months [2]. Similarly, STEP 1 participants maintained their weight loss through 68 weeks of treatment [3]. However, withdrawal studies for both medications show rapid weight regain when treatment stops, underscoring that these are chronic disease therapies rather than short-term interventions.

The STEP 4 trial specifically examined weight maintenance with semaglutide, randomising participants who had already lost weight on the medication to either continue treatment or switch to placebo [5]. Those continuing semaglutide maintained their weight loss and lost additional weight, whilst the placebo group regained approximately two-thirds of lost weight over 48 weeks. Similar withdrawal patterns have been observed with tirzepatide, suggesting both medications require ongoing use to sustain benefits.

Choosing Between Mounjaro and Wegovy: Clinical Considerations

UK prescribers weigh multiple factors when recommending between these treatments, including baseline BMI, comorbidities, previous treatment response, and patient preference. The clinical evidence suggests tirzepatide produces greater average weight loss, but individual response varies considerably.

Cost considerations also influence treatment selection. At Cured Pharmacy, Mounjaro is available from £124.99 following clinical assessment, whilst treatment costs and individual circumstances will be discussed during your consultation with a UK prescriber. Both medications require ongoing weekly injections, though patient preference surveys suggest similar acceptability for both delivery devices.

Patients with type 2 diabetes may particularly benefit from tirzepatide's superior HbA1c reduction demonstrated in SURPASS trials [1]. Conversely, those seeking the most established safety record may prefer semaglutide, which has been available longer and has more extensive post-marketing surveillance data. Your UK prescriber will assess your complete medical history, current medications, and treatment goals to recommend the most appropriate option for your individual circumstances.

Starting Your Treatment Journey

Both Mounjaro and Wegovy require a prescription from a UK-registered prescriber following clinical assessment. At Cured Pharmacy, our online consultation takes under three minutes and is reviewed by qualified UK clinicians. If approved, your medication is dispensed by our GPhC-registered pharmacy and delivered discreetly to your address. Regular follow-up consultations ensure safe dose titration and ongoing monitoring throughout your treatment journey.

Scientific References

  1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
  2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  4. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5 mg solution for injection in pre-filled pen. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/ [accessed 13 August 2026]
  5. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
  6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to prescribed treatment and lifestyle modifications.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Which is more effective for weight loss: Mounjaro or Wegovy?
Clinical trial evidence shows Mounjaro (tirzepatide) produces greater average weight loss than Wegovy (semaglutide), with participants in SURMOUNT-1 achieving 22.5% reduction at the highest dose versus 14.9% with semaglutide in STEP 1. Individual results vary and depend on adherence to lifestyle modifications alongside medication.
What does the mounjaro vs wegovy clinical evidence tell us about side effects?
Both medications have similar side effect profiles, with gastrointestinal symptoms (nausea, diarrhoea, vomiting) being most common in 60-80% of users. Discontinuation rates due to adverse events are comparable at 4-6% across clinical trials, suggesting similar real-world tolerability.
Has Mounjaro been directly compared to Wegovy in clinical trials?
Yes, the SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in adults with type 2 diabetes, showing superior weight loss with all tirzepatide doses. However, this compared against the 1mg diabetes dose rather than the 2.4mg obesity dose of semaglutide used in Wegovy.
How long does it take to see results with Mounjaro vs Wegovy?
Both medications produce gradual weight loss over months rather than weeks. In clinical trials, significant reductions became apparent after 12-16 weeks, with maximum effects observed at 60-72 weeks of continued treatment. Dose escalation schedules influence the timeline for both medications.
Can I switch from Wegovy to Mounjaro based on clinical evidence?
Switching between GLP-1 medications is possible under prescriber supervision, and some patients transition to tirzepatide seeking enhanced efficacy. Your UK prescriber will assess your current response, medical history, and treatment goals to determine if switching is appropriate for your circumstances.
Do Mounjaro and Wegovy work for everyone?
No weight loss medication works universally. In clinical trials, approximately 10-15% of participants did not achieve clinically meaningful weight loss (≥5%) even at maximum doses. Response depends on genetic factors, adherence, lifestyle modifications, and underlying metabolic conditions that your prescriber will evaluate.
What happens if I stop taking Mounjaro or Wegovy?
Clinical evidence from withdrawal studies shows most patients regain a significant proportion of lost weight when treatment stops, typically regaining two-thirds of weight loss within 48 weeks. Both medications are intended as long-term chronic disease treatments rather than short-term interventions.
Are Mounjaro and Wegovy available on the NHS?
Availability through NHS prescribing is limited and subject to strict eligibility criteria set by NICE. Many UK patients access these medications through private prescriptions from registered online pharmacies like Cured Pharmacy, where clinical assessment determines suitability and treatment can begin within days subject to prescriber approval.
What does the clinical evidence show between Mounjaro and Wegovy for weight loss?
Clinical trials show Mounjaro (tirzepatide) delivers superior weight loss compared to Wegovy, with patients losing up to 22.5% body weight versus 15% with semaglutide. Both medications are proven effective, but Mounjaro's dual GLP-1/GIP action provides enhanced results according to head-to-head UK and international studies.
Is Mounjaro more expensive than Wegovy in the UK?
Mounjaro starts from £124.99 at Cured Pharmacy, while Wegovy starts from £69.00 for the lowest dose. However, when comparing equivalent therapeutic doses, Mounjaro often provides better value given its superior clinical outcomes and faster weight loss results.
How quickly does Mounjaro work compared to Wegovy according to UK studies?
Clinical evidence suggests Mounjaro users often see faster initial weight loss than Wegovy patients, with significant results within 4-8 weeks. Both require dose escalation, but Mounjaro's dual-action mechanism typically accelerates metabolic changes and appetite suppression earlier in treatment according to comparative UK data.
Does the clinical evidence support using Mounjaro for diabetes like Wegovy?
Yes, both Mounjaro and Wegovy demonstrate excellent blood sugar control in clinical trials, though Mounjaro is specifically licensed for type 2 diabetes while Wegovy focuses on weight management. Cured Pharmacy can prescribe either medication based on your individual clinical needs and health goals after a thorough UK prescriber consultation.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.